Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended ...
April 29 2021 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating and developing small
molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal second quarter ended March 31, 2021, after the U.S. markets
close on May 6, 2021. Enanta management will host a conference call
at 4:30 p.m. ET to discuss these results and provide an update on
the company’s business, including its research and development
pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial
855-840-0595 in the U.S. or 518-444-4814 for international callers.
A replay of the conference call will be available starting at
approximately 7:30 p.m. ET on May 6, 2021, through 11:59 p.m. ET on
May 10, 2021 by dialing 855-859-2056 from the U.S. or 404-537-3406
for international callers. The passcode for both the live call and
the replay is 4283865. A
live audio webcast of the call and replay can be accessed by
visiting the “Events and Presentation” section on the “Investors”
page of Enanta’s website at www.enanta.com.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV)
and non-alcoholic steatohepatitis (NASH). Enanta is also conducting
research in human metapneumovirus (hMPV) and SARS-CoV-2
(COVID-19).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005041/en/
Media and Investor Contact: Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024